M
The startup develops personalized immunity drugs that target a novel endogenous immune activation factor network to treat infectious diseases with high mortality rates and intractable immune diseases resistant to current therapies. This approach enables medical practitioners to provide effective treatment options for patients who lack viable alternatives.
Incheon, South Korea
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops personalized immunity drugs that target a novel endogenous immune activation factor network to treat infectious diseases with high mortality rates and intractable immune diseases resistant to current therapies. This approach enables medical practitioners to provide effective treatment options for patients who lack viable alternatives.